Osteoarthritis · PDA-100

Ceres™ for the osteoarthritic joint

A single intra-articular application, studied against saline control across pain, function, and synovial inflammation.

VAS pain chart, Ceres vs saline

Study summary

In an in vivo study, a single intra-articular application reduced patient-reported pain (VAS) and functional deficit (JFLS) at 30 and 60 days versus saline, alongside lower inflammatory cytokine levels in synovial fluid.

Pain (VAS)

Reduced

at 30 and 60 days vs saline

Function (JFLS)

Improved

functional deficit reduced

Synovial cytokines

Lower

inflammatory markers in synovial fluid

Full clinical dossier

Complete study design, endpoints, and data tables are available to qualified practices on request.

© 2026 Ceres Biosolutions. This page is a temporary placeholder pending the full clinical detail page.

PDA-100